Drug intelligence / Profile preview

IQP-AS-119

Development stage: Unknown
Lead developer: InQpharm
Administration: Oral

Overview

IQP-AS-119 is a proprietary, standardized natural dietary supplement developed by InQpharm to support immune function and reduce susceptibility to upper respiratory tract infections (URTI) following extreme physical stress, such as marathon running. Clinical studies have demonstrated that IQP-AS-119 significantly reduces the incidence, duration, and severity of upper respiratory tract symptoms (URTS) in athletes during the post-exercise recovery period. It also appears to improve mental health scores and reduce perceived stress. The supplement is well-tolerated with a safety profile comparable to placebo.

Beyond the preview

Go deeper on IQP-AS-119.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IQP-AS-119.

Explore the full profile